Back to Search Start Over

Increased expression of regeneration and tolerance factor in individuals with human immunodeficiency virus infection.

Authors :
DuChateau BK
Lee GW
Westerman MP
Beaman KD
Source :
Clinical and diagnostic laboratory immunology [Clin Diagn Lab Immunol] 1999 Mar; Vol. 6 (2), pp. 193-8.
Publication Year :
1999

Abstract

Regeneration and tolerance factor (RTF) plays a pivotal role in successful pregnancy outcome and has potent immunomodulating properties. During pregnancy, it is abundantly expressed in the placenta and on peripheral B lymphocytes. Several lines of evidence suggest that both successful pregnancy outcome and progression from human immunodeficiency virus (HIV) infection to AIDS are associated with a Th2-type response. As a result, we hypothesized that the cellular expression of RTF may also be increased during infection with HIV. Using flow cytometric analysis, we showed a significantly (P < 0.01) increased expression of RTF on CD3(+) cells obtained from individuals with HIV over that for individuals without HIV. On average, 32.1% of the CD3(+) cells from individuals with HIV expressed high levels of RTF. In contrast, an average of only 6.7% of the CD3(+) cells from individuals without HIV expressed high levels of RTF. Similar results were obtained when CD19(+) cells from individuals with (mean, 44.1%) and without (mean, 25.8%) HIV were evaluated. Linear regression analysis suggested that high levels of RTF expression by CD3(+) cells correlated better with viral load (r value, 0.46) than with absolute CD4 count (r value, 0.09). While additional experiments are necessary to delineate the precise immunologic role of RTF, our current data suggest that RTF expression during HIV infection may be a useful marker of immune activation.

Details

Language :
English
ISSN :
1071-412X
Volume :
6
Issue :
2
Database :
MEDLINE
Journal :
Clinical and diagnostic laboratory immunology
Publication Type :
Academic Journal
Accession number :
10066653
Full Text :
https://doi.org/10.1128/CDLI.6.2.193-198.1999